非酒精性脂肪性肝炎的当前治疗方法与新进展
Current therapies and new developments in NASH.
作者信息
Dufour Jean-François, Anstee Quentin M, Bugianesi Elisabetta, Harrison Stephen, Loomba Rohit, Paradis Valerie, Tilg Herbert, Wong Vincent Wai-Sun, Zelber-Sagi Shira
机构信息
Centre des Maladies Digestives, Lausanne, Switzerland
Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
出版信息
Gut. 2022 Jun 16;71(10):2123-34. doi: 10.1136/gutjnl-2021-326874.
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
非酒精性脂肪性肝炎正成为晚期肝病的最重要病因。近年来该领域取得了重要进展，对非酒精性脂肪性肝炎病理生理学的复杂性有了更好的理解。多种非侵入性循环和成像生物标志物已得到测试。生活方式的重要性已得到认可，几种药物正在临床试验中接受测试。本综述探讨了医疗保健专业人员在非酒精性脂肪性肝炎患者管理中面临的挑战。
Zotero 插件